Nasdaq:SPRO
Spero Therapeutics, Inc.
A clinical-stage biopharmaceutical firm developing curative therapies for rare genetic diseases with a focus on Pompe disease.
Key Metrics
Investment Thesis
Bull Case
Investors may view this stock as a high-risk, high-reward opportunity given the transformative potential of its rare disease gene therapy pipeline which could generate substantial revenue upon approval and market uptake. The company's focus on underserved markets with few alternatives provides a unique positioning for premium pricing if clinical trials succeed. A successful data readout or strategic partnership could reset valuation multiples significantly higher than current levels.
Bear Case
The stock carries extreme downside risk due to its deteriorating financial health, evidenced by a $68.6M net loss and a severe revenue contraction that undermines business sustainability. With only $52.9M in cash remaining against ongoing burn rates exceeding $20M annually, the company faces an imminent liquidity crisis without immediate financing or commercial success. The lack of common share issuances suggests capital preservation is failing to counteract the rapid depletion of resources.
About Spero Therapeutics, Inc.
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare genetic disorders, primarily targeting conditions like Pompe disease. The company operates within the highly regulated medical device and gene therapy sectors, serving patients through specialized healthcare networks. Its revenue stream relies heavily on its proprietary product portfolio, though recent financials indicate significant volatility in commercial performance.
Analysis
Management Discussion
The company reported a net loss of $68.6M in 2024, marking a sharp reversal from the profitability seen in 2023, while revenue contracted significantly to $48.0M from $103.8M the prior year. Despite having $52.9M in cash and equivalents, the substantial operating expenses of $121.3M driven by $96.8M in research and development indicate an aggressive growth strategy that is currently consuming liquidity without matching revenue expansion. The shift from profit to loss suggests potential commercial headwinds or increased investment costs that management must address before cash reserves are depleted.
Industry Overview
The rare disease biopharmaceutical sector is characterized by high R&D costs, small patient populations, and complex regulatory pathways that require significant time and capital to navigate. Companies in this space often rely on breakthrough therapies with potential for high pricing power but face uncertainty regarding insurance coverage and reimbursement rates. Success depends heavily on the ability to deliver clinical data demonstrating meaningful patient outcomes over traditional treatments.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $53.5M | $103.8M | $48.0M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $53.5M | $103.8M | $48.0M |
| Operating Expenses | $95.7M | $82.3M | $121.3M |
| Operating Income | $-42.2M | $21.5M | $-73.4M |
| R&D | $47.6M | $51.4M | $96.8M |
| G&A | $36.5M | $25.6M | $23.7M |
| Stock-Based Comp | $9.1M | $7.9M | $7.8M |
| D&A | $869.0K | $367.0K | $2.0K |
| Other OpEx | $11.6M | $5.3M | $877.0K |
| Non-Operating Income | $-4.2M | $3.9M | $4.8M |
| Interest Income | $1.1M | $3.9M | $4.7M |
| Pre-Tax Income | $-46.4M | $25.4M | $-68.6M |
| Income Tax | $0 | $2.6M | $0 |
| Continuing Ops | $-46.4M | $22.8M | $-68.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-46.4M | $22.8M | $-68.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-46.4M | $22.8M | $-68.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $113.6M | $131.2M | $107.3M |
| Cash & Equivalents | $109.1M | $76.3M | $52.9M |
| Marketable Securities | $0 | — | — |
| Prepaid Expenses | $3.4M | $4.2M | $1.9M |
| Other Current Assets | $1.1M | $50.7M | $52.5M |
| Long-Term Assets | $11.2M | $51.2M | $3.3M |
| PP&E (Net) | $368.0K | $2.0K | $0 |
| Operating Leases | $5.1M | $4.2M | $3.1M |
| Other LT Assets | $5.7M | $47.0M | $153.0K |
| Total Assets | $124.8M | $182.4M | $110.5M |
| Current Liabilities | $21.6M | $37.2M | $49.1M |
| Accounts Payable | $617.0K | $1.4M | $7.3M |
| Current Leases | $1.7M | $1.7M | $1.7M |
| Other Current Liab | $19.3M | $34.1M | $40.0M |
| Long-Term Liabilities | $27.2M | $38.3M | $15.3M |
| LT Operating Leases | $5.0M | $3.8M | $2.6M |
| Other LT Liab | $22.3M | $34.5M | $12.8M |
| Total Liabilities | $48.9M | $75.5M | $64.4M |
| Shareholders' Equity | $75.9M | $106.9M | $46.1M |
| Retained Earnings | $-413.9M | $-391.1M | $-459.6M |
| AOCI | $0 | $0 | — |
| Total L&E | $124.8M | $182.4M | $110.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-46.4M | $22.8M | $-68.6M |
| Non-Cash Adjustments | $29.1M | $-84.8M | $29.7M |
| Working Capital Changes | $9.6M | $29.0M | $15.4M |
| Cash from Operations | $-7.7M | $-33.0M | $-23.4M |
| Cash from Investing | $33.8M | $0 | $0 |
| Cash from Financing | $-29.6M | $221.0K | $0 |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-3.5M | $-32.8M | $-23.4M |
| Beginning Cash | $112.6M | $109.1M | $76.3M |
| Ending Cash | $109.1M | $76.3M | $52.9M |
Frequently Asked Questions
How does Spero Therapeutics, Inc. make money?
Revenue derived primarily from sales of proprietary medical devices and drug products targeting rare genetic disorders, with operations centered on the United States market.
What are the main risks for SPRO?
Significant cash burn rate of $23.4M annually creating near-term liquidity pressure given limited cash reserves; high volatility in commercial revenue dropping 54% year-over-year in 2024; reliance on successful clinical trial outcomes for future value creation; potential regulatory delays or reimbursement challenges for novel gene therapies.
What is SPRO's competitive advantage?
Proprietary gene therapy platforms offering potential one-time curative treatments for severe rare diseases; specialized clinical trial expertise in ultra-rare patient populations; established partnerships with key healthcare providers for patient identification and treatment delivery.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.